Paratesticular Rhabdomyosarcoma: Report From the Italian and German Cooperative Group

Abstract

The outcome for patients with localized paratesticular rhabdomyosarcoma is excellent, despite the reduction in chemotherapy over the years: an alkylating agent-free and anthracycline-free regimen is adequate treatment for low-risk patients. Surgical assessment of the retroperitoneum must be reserved for patients with enlarged nodes on CT scans. Children over 10 years old carry a higher risk of nodal involvement and relapse.

Mixed‐type paratesticular rhabdomyosarcoma—A case report

“…The treatment of paratesticular RMS has evolved considerably over the past several decades. Cure rates have risen, largely because of increasingly intensive multimodality therapeutic protocols that have been developed by large international cooperative groups, such as the Intergroup Rhabdomyosarcoma Study Group [4]. Histologically, any subtype of RMS may occur in the paratesticular region, although the most common are embryonal, alveolar, and pleomorphic.…”

Embryonal paratesticular rhabdomyosarcoma: a case of young adult patient who has inguinal relapse

“…Paratesticular rhabdomyosarcomas are treated with combined treatment protocols. These protocols include inguinal radical orchiectomy, local radiotherapy to eliminate microscopic and macroscopic residual tumors, and multiple chemotherapy protocols [3]. Five-year survivals are reported to be over 80% with these treatment protocols [3,4].…”

“…The mass completely disappeared after the treatment. Retroperitoneal lymph node dissection is generally not recommended for the primary treatment or staging [1][2][3][4].…”

Adult paratesticular rhabdomyosarcoma

“…Paratesticular rhabdomyo sarcoma patients in IRS Group IV have an extremely poor prognosis, with a 5-year survival rate of 22.2%, while patients in Groups I-III have a 5-year survival rate of 94.6%. 8 In this case, the patient's clinical stage was initially thought to be Group I, since the CT scan revealed no evidence of metastasis. However, following retroperitoneal lymph-node dissection, lymphnode meta stasis was found and the patient was reclassified as Group IIB.…”